AU2023266749A1 - Fusion protein of relaxin or analogue and medical use thereof - Google Patents

Fusion protein of relaxin or analogue and medical use thereof Download PDF

Info

Publication number
AU2023266749A1
AU2023266749A1 AU2023266749A AU2023266749A AU2023266749A1 AU 2023266749 A1 AU2023266749 A1 AU 2023266749A1 AU 2023266749 A AU2023266749 A AU 2023266749A AU 2023266749 A AU2023266749 A AU 2023266749A AU 2023266749 A1 AU2023266749 A1 AU 2023266749A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
set forth
serum albumin
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023266749A
Other languages
English (en)
Inventor
Yanping DU
Hong Gao
Peng Jiang
Xiao Liu
Chenxi SHEN
Lei Wang
Linshuang ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tuo Jie Biopharmaceutical Co Ltd
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of AU2023266749A1 publication Critical patent/AU2023266749A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2023266749A 2022-05-07 2023-05-05 Fusion protein of relaxin or analogue and medical use thereof Pending AU2023266749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210491720.7 2022-05-07
CN202210491720 2022-05-07
PCT/CN2023/092214 WO2023216981A1 (zh) 2022-05-07 2023-05-05 松弛素或类似物的融合蛋白及其医药用途

Publications (1)

Publication Number Publication Date
AU2023266749A1 true AU2023266749A1 (en) 2024-11-07

Family

ID=88729678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023266749A Pending AU2023266749A1 (en) 2022-05-07 2023-05-05 Fusion protein of relaxin or analogue and medical use thereof

Country Status (10)

Country Link
US (1) US20250312444A1 (cg-RX-API-DMAC7.html)
EP (1) EP4524156A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025517100A (cg-RX-API-DMAC7.html)
KR (1) KR20250009454A (cg-RX-API-DMAC7.html)
CN (1) CN119032105A (cg-RX-API-DMAC7.html)
AU (1) AU2023266749A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252059A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013712A (cg-RX-API-DMAC7.html)
TW (1) TW202409074A (cg-RX-API-DMAC7.html)
WO (1) WO2023216981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN122122198A (zh) * 2023-11-08 2026-05-29 北京拓界生物医药科技有限公司 融合蛋白及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2766160A1 (en) * 2000-12-12 2002-08-08 William Dall'acqua Modified molecules with increased affinity for fcrn, compositions, and uses thereof
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AU2012283235A1 (en) * 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
KR20160071472A (ko) 2013-11-07 2016-06-21 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 릴렉신 유사체, 이의 약제학적 조성물 및 이의 약제학적 적용
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
CN112851805B (zh) * 2019-11-12 2025-09-09 四川科伦博泰生物医药股份有限公司 一种结合血清白蛋白的蛋白及其用途
CR20230015A (es) 2020-06-17 2023-02-17 Medimmune Ltd Fusiones heterodiméricas de relaxina y usos de las mismas

Also Published As

Publication number Publication date
JP2025517100A (ja) 2025-06-03
CN119032105A (zh) 2024-11-26
MX2024013712A (es) 2024-12-06
CA3252059A1 (en) 2025-07-07
TW202409074A (zh) 2024-03-01
US20250312444A1 (en) 2025-10-09
WO2023216981A1 (zh) 2023-11-16
EP4524156A4 (en) 2025-10-22
KR20250009454A (ko) 2025-01-17
EP4524156A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US11780923B2 (en) PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
KR102944460B1 (ko) Cldn18.2 및 cd3에 대한 항체 작제물
JP6313712B2 (ja) 新生児Fc受容体への結合を強化された変異型Fcポリペプチド
JP5501765B2 (ja) 血栓症の処置のための抗糖タンパク質vi scfvフラグメント
US20250312444A1 (en) Fusion protein of relaxin or analogue and medical use thereof
US11773185B2 (en) Anti-BACE1 antibodies and methods of use thereof
US20220185875A1 (en) Bispecific antibody specifically bound to vegf and ang2
CN111744013A (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
Simmons et al. Dimerisation strategies for shark IgNAR single domain antibody fragments
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
WO2019094576A1 (en) Bace-tau bispecific antibodies
CN112996811B (zh) 双特异性蛋白
US20240124575A1 (en) Human cd33 antibody and use thereof
AU2023373925A1 (en) Bispecific antibody for glypican-3 and use thereof
CN119119280A (zh) FXII/FXIIa结合蛋白及其医药用途
JP7010491B2 (ja) ヒト化抗rage抗体
US20240002497A1 (en) Nav1.7 binders
RU2784486C1 (ru) Биспецифический белок
WO2025098472A1 (zh) 融合蛋白及其医药用途
WO2025099632A1 (en) Cd25 based lysosomal degrader and uses thereof
WO2025041077A1 (en) Ctla-4-based lysosomal degraders and uses thereof
WO2026056998A1 (zh) Gipr结合分子及医药用途
TW202436343A (zh) Muc1與cd16a抗體以及其使用方法